Big Japanese Pharmas Unlikely To Replace Expiring Patents With M&As
This article was originally published in PharmAsia News
Executive SummaryAnalysts believe the mergers-and-acquisitions drive of Japan's large drug makers is not likely to fill the void the companies face as their best-selling brands lose patent protection. Several Japanese pharmas have acquired foreign firms to help refill their dwindling portfolios, but analysts say that move is not likely to be enough to keep the companies from falling off what one said was a patent cliff. Drug makers in other countries have faced similar problems over the past 10 years, but this is the first time Japanese pharmas have faced the cliff. So far, Daiichi Sankyo is the only large maker that has not faced the loss of patent protection for a major drug. (Click here for more
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.